Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Agios Pharmaceuticals, Inc. (AGIO : NSDQ)

• Company Description    Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases. Number of Employees: 392

• Price / Volume Information    Yesterday's Closing Price: $21.10 Daily Weekly Monthly 20 Day Moving Average: 698,001 shares Shares Outstanding: 54.79 (millions) Market Capitalization: $1,156.05 (millions) Beta: 1.51 52 Week High: $62.16 52 Week Low: $19.97 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.33% -4.64% 12 Week -27.57% -20.37% Year To Date -35.81% -23.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 88 SIDNEY STREET - CAMBRIDGE,MA 02139 USA ph: 617-649-8600 fax: - investors@agios.com http://www.agios.com

• General Corporate Information    Officers Jacqualyn A. Fouse - ChiefExecutiveOfficerand Director Jonathan Biller - Chief Financial Officer and Head of Corporate Affa Paul J. Clancy - Director Ian Clark - Director Kaye Foster - Director Peer Information Agios Pharmaceuticals, Inc. (BJCT) Agios Pharmaceuticals, Inc. (CADMQ) Agios Pharmaceuticals, Inc. (APNO) Agios Pharmaceuticals, Inc. (UPDC) Agios Pharmaceuticals, Inc. (IMTIQ) Agios Pharmaceuticals, Inc. (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 00847X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 54.79 Most Recent Split Date: (:1) Beta: 1.51 Market Capitalization: $1,156.05 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.78 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-7.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 7.33% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.96 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -32.82% vs. Previous Quarter: 3.87% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -25.67 12/31/21 - -21.27 09/30/21 - -24.47 ROA 03/31/22 - -23.29 12/31/21 - -19.42 09/30/21 - -21.05 Current Ratio 03/31/22 - 21.30 12/31/21 - 17.79 09/30/21 - 22.55 Quick Ratio 03/31/22 - 21.24 12/31/21 - 17.79 09/30/21 - 22.55 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -43,318.15 12/31/21 - - 09/30/21 - -777.54 Book Value 03/31/22 - 22.04 12/31/21 - 23.79 09/30/21 - 25.68 Inventory Turnover 03/31/22 - 0.55 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.02 12/31/21 - 0.02 09/30/21 - 0.00

Powered by Zacks Investment Research ©